<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424229</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-REV-2006-02</org_study_id>
    <nct_id>NCT00424229</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]</brief_title>
  <official_title>Phase II Study of the Efficacy and Safety of Lenalidomide in Adult Subjects With Intermediate-2-or Higt Risk Myelodysplastic Syndrome(MDS) Associated With a Deletion (DEL) 5q [31]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are evaluating the incidence of significant hematological response, according to IWG
      criteria including CR, PR or, major HI, (HI-E, Hl-N,or Hl- P), and cytogenetic response of
      patients diagnosed with intermediate-2 or high-risk (International Prognostic Scoring System
      [IPSS]) MDS with a deletion (del) 5q[31]
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects meeting all inclusion and exclusion criteria will receive lenalidomide

      lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every
      4 weeks.

      Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and
      when clinically indicated/for assessment of disease progression) evaluations

      Subjects may participate in the study for up to 52 weeks ( in patients still responding after
      52 weeks, the drug wil continue to be supplied).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date>October 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: Complete Response; Partial ResponseSecondary: Hematological Improvement</measure>
  </primary_outcome>
  <enrollment>49</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LENALIDOMIDE</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years at the time of signing the informed consent form

          -  MDS with IPSS scores Int-2 or high with deletion 5q(31)

          -  Prior thalidomide allowed

          -  Documented diagnosis of MDS (RA, RARS, RAEB, RAEB-T and CMML with WBC &lt; 13,000/mm3
             according to FAB classification) that meets IPSS criteria for intermediate-2 or
             high-risk disease and has an associated del 5q[31] (the deleted chromosomal region
             must include 5q[31]), with or without additional cytogenetic abnormalities

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Prior therapy with lenalidomide

          -  MDS with IPSS scores low or Int-1

          -  Clinical neuropathy of greater than grade 2

          -  Proliferative (WBC ≥ 13,000/mL) chronic myelomonocytic leukemia (CMML)

          -  Recombinant human erythropoietin (rHuEPO) therapy received within 28 days

          -  Use of androgens other than for treating hypogonadism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre FENAUX, Profesor</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Francophone des Myelodysplasies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara Burcheri</last_name>
    <role>Study Director</role>
    <affiliation>Groupe français des myélodysplasies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>.Pierre FENAUX, Professor</last_name>
    <phone>0033148955070</phone>
    <email>pierre.fenaux@avc.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatrima-Zohra HAMZA, CRA</last_name>
    <phone>0033148955890</phone>
    <email>fatima.hamza@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde HUNAULT-BERGER, MD</last_name>
      <phone>0033241354475</phone>
      <email>MHunault@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>HUNAULT-BERGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Hurriez</name>
      <address>
        <city>Lille</city>
        <zip>59057</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno QUESNEL, Profesor</last_name>
      <phone>0033320446640</phone>
      <email>b-quesnel@chru.fr</email>
    </contact>
    <investigator>
      <last_name>QUESNEL, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert VEY, MD</last_name>
      <phone>0033431223695</phone>
      <email>veyn@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>VEY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>CHARBONNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GASTAUT, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BOUABDALLAH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>REY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>STOPPA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc HAROUSSEAU</last_name>
      <phone>0033240083271</phone>
    </contact>
    <investigator>
      <last_name>Jacques Delaunay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence LEGROS</last_name>
      <phone>0033492035844</phone>
      <email>legros.l@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>LEGROS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoiptal St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve DOMBRET, Profesor</last_name>
      <phone>0033142499643</phone>
      <email>herve.dombret@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé Dombret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois DREYFUS, Professor</last_name>
      <phone>003358412120</phone>
      <email>francois.dreyfus@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>DREYFUS, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jean-Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois GUILHOT, Professor</last_name>
      <phone>0033549444201</phone>
      <email>f.guilhot@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>GUILHOT, Profesor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ROY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henry Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76 038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aspasia Stamatoullas, MD</last_name>
      <phone>33 2 32 08 22 88</phone>
      <email>aspsta@rouen.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia Stamatoullas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile BEYNE-RAUZY, Doctor</last_name>
      <phone>0033561779679</phone>
      <email>beynerauzy.o@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Odile BEYNE-RAUZY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes GUERCI-BRESLER, MD</last_name>
      <phone>0033383153281</phone>
      <email>a.guerci@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>GUERCI-BRESLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>March 9, 2007</last_update_submitted>
  <last_update_submitted_qc>March 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2007</last_update_posted>
  <keyword>MDS INT-2MDS HIGH RISKDELETION 5q[31]Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

